Time to Update & quot;Routine, Repeated & quot; Use of Bone Metastasis Drugs Time to Update & quot;Routine, Repeated & quot; Use of Bone Metastasis Drugs
Dr Mark Kris discusses the use of zoledronic acid and denosumab for preventing problems brought on by bone metastases.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 2, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
Class 4 medicine defect information: zoledronic acid 5mg solution for infusion
Ranbaxy (UK) Ltd a Sun Pharmaceutical Company, has informed the MHRA that some packs from a batch of zoledronic acid 5mg solution for infusion contain a patient information leaflet for temozolomide 18 (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - April 4, 2019 Category: Drugs & Pharmacology Source Type: news
Zoledronic Acid (Zometa) Injection (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - October 30, 2018 Category: Drugs & Pharmacology Source Type: news
Zoledronic acid improves disease-free survival in premenopausal HR+ early breast cancer
(European Society for Medical Oncology) Adjuvant treatment with the bone sparing drug zoledronic acid plus hormonal therapy with the aromatase inhibitor letrozole significantly increases disease-free survival compared to tamoxifen in premenopausal women with hormone receptor positive (HR+) early breast cancer, according to results reported at ESMO 2018 Congress in Munich. It is the first study to assess this specific combination in premenopausal breast cancer and adds to previous observations with zoledronic acid and anastrozole in premenopausal women receiving ovarian suppression. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 22, 2018 Category: Cancer & Oncology Source Type: news
Zoledronic Acid Superior to ART-switching for Low Bone Density in HIV Zoledronic Acid Superior to ART-switching for Low Bone Density in HIV
Zoledronic acid improves low bone mineral density (BMD) better than switching from tenofovir disoproxil fumarate (TDF) to another antiretroviral drug in adults with HIV, researchers report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 18, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news
Acute Phase Reactions After Zoledronic Acid Infusion Acute Phase Reactions After Zoledronic Acid Infusion
Might previous treatment with oral amino-bisphosphonates and higher 25(OH)D levels be protective factors for acute phase reaction to zoledronic acid infusion?Endocrine Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 17, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Zoledronic Acid Prevents Bone Loss in Premenopausal Breast-Cancer Patients Zoledronic Acid Prevents Bone Loss in Premenopausal Breast-Cancer Patients
Zoledronic acid can prevent treatment-related bone loss in premenopausal breast-cancer patients, and the benefit persists for up to three years after treatment, according to new findings.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 26, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news
Zoledronic acid has no effect on knee pain or bone marrow lesions in knee OA after two years
(European League Against Rheumatism) The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) show that a one-yearly infusion of zoledronic acid (ZA) did not significantly reduce knee pain or bone marrow lesion (BML) size overall in knee osteoarthritis patients over two years. However, it may have symptomatic benefit in milder disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 15, 2018 Category: International Medicine & Public Health Source Type: news
Osteoporosis drug could be used to treat aggressive form of breast cancer, researchers say
(Rockefeller University Press) Researchers in China have discovered that an enzyme called UGT8 drives the progression of basal-like breast cancer, an aggressive form of the disease that is largely untreatable. But the study, which will be published May 4 in the Journal of Experimental Medicine, reveals that the widely used osteoporosis drug zoledronic acid inhibits UGT8 and prevents the spread of basal-like breast cancer in mice, suggesting that this drug could also be used to treat the disease in humans. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 4, 2018 Category: Cancer & Oncology Source Type: news
In Central America, New Adherence Promoters Keep HIV Clients on Treatment
March 02, 2018Carlos considered dropping out of everything. Then he met Aracely, an adherence promoter.Carlos* remembers the exact date he found out he was HIV-positive. He was 20 years old.“January 20, 2015. I was walking with some friends and, over in the square, we saw a tent where they were giving HIV tests,” he says. “As a group of nursing assistants, we said, ‘Let’s do this! Why not?’”Carlos sat alone as he waited for his results. He was #45 in the queue that day.“When they told me I needed additional tests because my results were reactive to virus, I felt my world falling apart,” says Carlos. “I ...
Source: IntraHealth International - March 2, 2018 Category: International Medicine & Public Health Authors: cbales Source Type: news
